Format

Send to:

Choose Destination
See comment in PubMed Commons below
Chem Res Toxicol. 2014 May 19;27(5):738-40. doi: 10.1021/tx500108u. Epub 2014 May 2.

IgG3 is the dominant subtype of anti-isoniazid antibodies in patients with isoniazid-induced liver failure.

Author information

  • 1Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto , Toronto, Ontario M5S 1A8, Canada.

Abstract

Isoniazid (INH) therapy is associated with a significant incidence of idiosyncratic liver failure. We recently reported eight cases of INH-induced liver failure in which patients had antidrug and anticytochrome P450 antibodies. However, it was unclear what role these antibodies play in the mechanism of INH-induced liver injury. Here, we report that the dominant isotype of anti-INH antibodies was IgG, with IgG3 being the dominant subtype. IgG3 antibodies are associated with a Th1-type immune response and fix complement. IgG3 antibodies have been associated with other forms of liver injury and may play a pathogenic role in INH-induced liver injury.

PMID:
24786179
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Chemical Society
    Loading ...
    Write to the Help Desk